NCT00017862View on ClinicalTrials.gov

Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2001

Study Completion Date

June 30, 2003

Conditions
Hypereosinophilic Syndrome
Interventions
DRUG

SCH55700

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00017862 - Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome | Biotech Hunter | Biotech Hunter